<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04229888</url>
  </required_header>
  <id_info>
    <org_study_id>1908329543</org_study_id>
    <nct_id>NCT04229888</nct_id>
  </id_info>
  <brief_title>Meibomian Gland Dysfunction Treatment</brief_title>
  <official_title>Meibomian Gland Dysfunction Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indiana University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Indiana University School of Optometry</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Indiana University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effectiveness of treatments for Meibomian Gland
      Dysfunction.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 27, 2020</start_date>
  <completion_date type="Anticipated">October 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>All subjects will receive first treatment and then second treatment. The eye receiving treatment will be randomly selected. The same eye will receive both treatments.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in DEQ-5 score</measure>
    <time_frame>2 weeks</time_frame>
    <description>DEQ5 total score ranges from 0-22 with the higher scores indicating increased dry eye.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in meibomian gland score</measure>
    <time_frame>2 weeks</time_frame>
    <description>Meibomian glands evaluated on the lower eyelid using meibomian gland evaluator. 5 glands in 3 regions (nasal, central, temporal) evaluated and scored from 0 to 4 for a max score of 60 in each eye. (MGS scale 0 = clear, 1 = cloudy, 2 = granular, 3 = pastelike, 4 = obstruction)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Tear Break-Up Time (TBUT)</measure>
    <time_frame>2 weeks</time_frame>
    <description>Tear break-up time (defined as the time required for dry spots to appear on the surface of the eye after blinking) was assessed by the examiner using a slit lamp and fluorescein strips. Fluorescein was instilled onto the patient's eye, after which the patient blinked three times, then kept the eye open. Immediately thereafter, the examiner used a stopwatch to record the time between the last blink and the first appearance of a dark spot on the cornea (formation of dry area). Three consecutive measurements were taken and averaged for actual TBUT. A positive change value represents a lengthening in the tear break-up time and greater comfort.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Meibomian Gland Dysfunction</condition>
  <condition>Dry Eye</condition>
  <arm_group>
    <arm_group_label>Subjects Treatment 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects will receive light based treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects Treatment 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects will receive LipiFlow treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>LipiFlow</intervention_name>
    <description>Medical device that applies a combination of heat and pressure to the inner eyelid to remove gland obstructions and stagnant gland content</description>
    <arm_group_label>Subjects Treatment 2</arm_group_label>
    <other_name>Johnson &amp; Johnson</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Light Based Treatment</intervention_name>
    <description>A light based treatment will be used to compare effectiveness to the LipiFlow treatment.</description>
    <arm_group_label>Subjects Treatment 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  evidence of meibomian gland obstruction in both eyes

          -  dry eye symptoms per DEQ-5

        Exclusion Criteria:

          -  active ocular infection

          -  previous LipiFlow treatment

          -  beginning new oral or other systemic medications within prior 3 months

          -  beginning new or changing dosages of ocular medications within prior 3 months

          -  previous ocular surgery, trauma, herpes, recurrent inflammation, punctal plugs in
             prior 3 months

          -  habitual contact lens wear in prior 3 months

          -  women who are pregnant or nursing
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Anna Tichenor</last_name>
    <phone>8128550520</phone>
    <email>annatich@iu.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jennifer Pence</last_name>
    <phone>8128556261</phone>
    <email>jmpence@indiana.edu</email>
  </overall_contact_backup>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 13, 2020</study_first_submitted>
  <study_first_submitted_qc>January 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 18, 2020</study_first_posted>
  <last_update_submitted>January 13, 2020</last_update_submitted>
  <last_update_submitted_qc>January 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Indiana University</investigator_affiliation>
    <investigator_full_name>Anna Tichenor</investigator_full_name>
    <investigator_title>Assistant Scientist</investigator_title>
  </responsible_party>
  <keyword>dry eye</keyword>
  <keyword>meibomian gland dysfunction</keyword>
  <keyword>lipiflow</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Dry Eye Syndromes</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

